Nautilus Biotechnology Q3 2026 earnings Call - NAUTILUS BIOTECHNOLOGY INC

Financial Performance:

• Q3 2026 total revenue was $0.2 million, derived from grant funding (Michael J. Fox Foundation) and Early Access service revenue.
• Total operating expenses were $16.9 million (up 10% YoY), with R&D at $10.2 million (+6%) and G&A at $6.8 million (+15%).
• Net loss for Q3 2026 was $15.6 million ($0.12 per share), compared to $13.6 billion in the prior year period (likely a reporting typo in transcript, context suggests a smaller loss or specific context, but text reads "$13.6 billion").
• Cash and investments stood at $114.3 million as of Q3 2026, with a cash burn of ~$14.9 million in the quarter.
• Company projects a cash runway extending into Q1 2028 and expects Q4 revenue to grow sequentially due to Early Access activity and SEEDS grant recognition.
• Full-year 2026 revenue guidance has been raised to exceed $0.5 million.

Guidance and Future Outlook:

• Commercial launch of the Voyager platform and pre-orders are targeted for mid-2027, with instrument shipments and general availability of Tau and AKT1 kits scheduled for mid-2027.
• Company aims to develop 20 proteoform assays by mid-2028; current roadmap includes AKT1, EGFR, and P53 assays in various development stages.
• Sample input requirements are expected to decrease by 100-fold before mid-2027 to enable measurement of low-abundance proteins in biofluids.
• Commercial scaling is anticipated to accelerate in 2028 following the completion of S10 grant cycles initiated in 2027.
• Management is evaluating a potential capital raise between now and mid-2027 to fund portfolio expansion, platform capabilities, and commercial team growth.

Business Segments and Product Lines:

• Core technology "Voyager" utilizes "iterative mapping" to measure intact protein proteoforms at single-molecule resolution, distinct from traditional shotgun mass spectrometry.
• Early Access Program is the current revenue engine, with initial customers including Baylor College of Medicine.
• Three oncology assays (AKT1, EGFR, P53) are currently in development, with AKT1 expected to enter Early Access in late 2026.
• SEEDS Consortium partnership (funded by ARPA-H, up to $51.7M total) will apply the platform to Tau in Alzheimer's and EWS-FLI1 in Ewing's sarcoma over four years.
• Collaboration with the Michael J. Fox Foundation is underway for an alpha-synuclein proteoform assay for Parkinson's disease.

Market and Competitive Landscape:

• Proteoforms are identified as a critical, unmet market need for drug development and precision medicine, validated by the theme at the HUPO World Congress 2026.
• The platform is positioned as unique due to its ability to provide reproducible data with median coefficients of variation (CV) between 3.6% and 8.8%, significantly lower than the 20-40% CVs typical of current mass spectrometry methods.
• Early customers are primarily in academia and nonprofit research, with a strategic shift toward pharma and large-scale commercial cohorts expected in 2027-2028.
• The company views high-quality proteoform data as a foundational requirement for training next-generation AI models in biomedicine.

Risks and Challenges:

• Financial risk: Company is in a pre-commercial phase with significant net losses and relies on grant funding and Early Access revenue until instrument sales mature.
• Market adoption risk: Success depends on customers transitioning from service models to instrument purchases, which historically requires high consumable volume (approx. $0.5M annually per instrument).
• Funding uncertainty: Potential volatility in NIH S10 grant cycles for instrument purchases could impact early revenue growth in 2027.
• Execution risk: Roadmap depends on successfully commercializing multiple new assays (AKT1, EGFR, P53) and reducing sample input requirements by 100-fold.

Management Commentary and Tone:

• Tone is highly confident and strategic, emphasizing the uniqueness of the technology and the "compelling business opportunity" of proteoforms.
• Management framed the strategy as "making functional biology measurable," asserting no other competitor can currently deliver single-molecule resolution at scale.
• CEO Sujil Patel expressed strong confidence in the team's ability to execute, citing the rapid replication of Tau's reproducibility metrics in newer oncology targets.
• CFO Anna Mowry maintained a disciplined view on capital allocation while acknowledging the necessity of a future raise to scale.

Analyst Questions and Answers:

• SEEDS Funding: Revenue recognition is spread over the four-year program; funds are split between Buck Institute and Georgetown for Tau and EWS-FLI1 work.
• AI Data Opportunities: Management highlighted the lack of high-reproducibility data as a barrier for current AI models, positioning Nautilus as the provider of the "training set" needed for frontier biology models.
• Sales & Pipeline: A small three-person sales team has built a strong pipeline driven by the Nature Methods publication; Q4 growth is expected even without SEEDS contributions.
• Commercial Launch Strategy: Modeled after disruptive platforms like 10x Genomics; initial launch will feature specific assays in general availability with more in Early Access to drive instrument utilization.
• Early Access Use Cases: Key applications include differentiating cell line models (e.g., iPSC neurons), understanding selective vulnerability in Alzheimer's via regional Tau variations, and linking ApoE genetics to Tau pathology.

Other Key Points:

• The "Nature Methods" publication of Tau proteoform analysis served as a peer-reviewed validation of the iterative mapping method, with external commentary suggesting potential clinical utility for diagnosis and therapy monitoring.
• The company plans to focus on consumable kit sales rather than heavy capital expenditure on facilities; future CapEx will be targeted and not material to the burn rate.
• Instrument pricing and specifications are being finalized with the goal of taking pre-orders in early 2027.
• Management emphasized that long-term success relies on demonstrating actionable biological insight that directly impacts drug development efficacy and diagnostic stratification.